⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12104096 | 1.00 | — | — | |
| SCHEMBL3430471 | 1.00 | — | — | |
| SCHEMBL12104106 | 1.00 | — | — | |
| SCHEMBL8748332 | 1.00 | — | — | |
| SCHEMBL12360 | 1.00 | — | — | |
| SCHEMBL2609215 | 1.00 | — | — | |
| SCHEMBL12570742 | 1.00 | — | — | |
| SCHEMBL24743621 | 0.80 | EPHX2 (0.48) | — | |
| SCHEMBL22363782 | 0.78 | MAPT (0.31) | — | |
| SCHEMBL10416262 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348459-A1 | PYRROLIDINE COMPOUND AND USE THEREOF | SIMCERE PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348459-A1 | PYRROLIDINE COMPOUND AND USE THEREOF | SIMCERE PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| WO-2021228210-A1 | PYRROLIDINE COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2021-11-18 | — | — | WO | disclosed |
| WO-2020160010-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20170204110-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2017-07-20 | — | — | US | disclosed |
| WO-2017117239-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC (US) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017035360-A1 | COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |